MobiDrop

MobiDrop is an innovative technology company based on microfluidic technology, dedicated to precision diagnosis and life science research. It is China's first multi-platform new molecular diagnostics company. Based on the cutting-edge third-generation microfluidic technology patent portfolio from Harvard University, MobiDrop is committed to building a more precise, faster, and practical new molecular diagnostics and life science research platform. By upgrading diagnostics and testing quality, it enhances the level of life science research and provides more efficient solutions for researchers, doctors, and patients. MobiDrop is the first in China to simultaneously deploy digital PCR and single-cell sequencing platforms. The company’s product range includes integrated machine platforms, microfluidic detection chips, and supporting reagents, widely used in molecular diagnostics, cancer screening, and drug development. The core team consists of world-class scientists and senior executives from multinational large medical device companies, including Professor David Weitz, a member of the US National Academy of Sciences, the US National Academy of Engineering, and the US National Academy of Medicine, as well as a foreign academician of the Chinese Academy of Engineering, who serves as the chief scientist.